A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (Bortezomib, Velcade), in patients with advanced cancer

Clinical Cancer Research

Volumn 11, Issue 9, 2005, Pages 3410-3416

  Dy, Grace K ^a   Thomas, James P ^b   Wilding, George ^b   Bruzek, Laura ^a   Mandrekar, Sumithra ^a   Erlichman, Charles ^a   Alberti, Dona ^b   Binger, Kim ^b   Pitot, Henry C ^a   Alberts, Steven R ^a   Hanson, Lorelei J ^a   Marnocha, Rebecca ^b   Tutsch, Kendra ^b   Kaufmann, Scott H ^a   Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; PROTEASOME INHIBITOR;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER INHIBITION; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DOSE TIME EFFECT RELATION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOGLYCEMIA; HYPOTENSION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MYALGIA; NAUSEA; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SAMPLING; SENSORY NEUROPATHY; STOMATITIS; SYNCOPE; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC AGENTS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; BORONIC ACIDS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CYCLIN E; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; I-KAPPA B PROTEINS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRAZINES; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS; VOMITING;

EID: 20944450476     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2068     Document Type: Article

References (19)

1. Voorhees PM, Dees EC, O'Neil B, et al. The proteasome as a target for cancer therapy. Clin Cancer Res 2003;9:6316-25.
2. Jentsch S. Ubiquitin-dependent protein degradation: a cellular perspective.Trends Cell Biol 1992;2:98-103.
3. κ-B1 precursor protein and the activation of NF-B. Cell 1994;78:773-85.
4. Read MA, Neish AS, Luscinskas FW, et al. The proteasome pathway is required for cytokine-induced endothelial-leukocyte adhesion molecule expression. Immunity 1995;2:493-506.
5. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-22.
6. Teicher BA, Ava G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-45.
7. Lightcap ES, McCormack TA, Pien CS, et al. Proteasome inhibition measurements: clinical application. Clin Chem 2000;46:673-83.
8. Jagannath S, Barlogie B, Berenson J, et al. A phase II multicenter randomized study of the proteasome inhibitor bortezomib (VEL.CADE™, formerly PS-341) in multiple myeloma patients relapsed after front-line therapy. Blood 2002;100:3027a.
9. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17.
10. Orlowski RZ, StinchcombeTE, Mitchell BS, et al. Phase I trial of the proteasome inhibitor PS341 in patients with refractory hematologic malignancies. J Clin Oncol 2002;20:4420-7.
11. Cortes J.Thomas D, Koller C, et al. Phase I study of bortezomb in refractory or relapsed acute leukemias. Clin Cancer Res 2004;10:3371-6.
12. Papandreou C, Daliani D, Millikan RE, et al. Phase I study of intravenous proteasome inhibitor PS-341 in patients with advanced malignancies. J Clin Oncol 2004;22:2108-21.
13. Aghajanian C, Soignet S, Dizon DS, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002;8:2505-11.
14. Pagano M, Tam SW, Theodora AM, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;4:269:682-5.
15. Chang YC, Lee YS, Tejima T, et al. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ 1998;1:79-84.
16. Kazi A, Daniel KG, Smith DM, et al. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol 2003;66:965-76.
17. Fan XM, Wong BC, Wang WP, et al. Inhibition of proteasome function induced apoptosis in gastric cancer, Int J Cancer 2001;93:481-8.
18. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1987:150:76-85. Erratum in: Anal Biochem 1987:163:279.
19. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem 1987:150:76-85. Erratum in: Anal Biochem 1987:163:279.